Sol-Gel Technologies Debt to Equity Ratio 2016-2024 | SLGL

Current and historical debt to equity ratio values for Sol-Gel Technologies (SLGL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sol-Gel Technologies debt/equity for the three months ending June 30, 2024 was 0.00.
Sol-Gel Technologies Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-06-30 $0.01B $0.04B 0.20
2024-03-31 $0.01B $0.03B 0.22
2023-12-31 $0.01B $0.04B 0.17
2023-09-30 $0.01B $0.04B 0.16
2023-06-30 $0.01B $0.05B 0.14
2023-03-31 $0.01B $0.04B 0.11
2022-12-31 $0.00B $0.04B 0.11
2022-09-30 $0.00B $0.05B 0.08
2022-06-30 $0.01B $0.05B 0.09
2022-03-31 $0.01B $0.05B 0.12
2021-12-31 $0.01B $0.06B 0.25
2021-09-30 $0.01B $0.04B 0.28
2021-06-30 $0.01B $0.04B 0.18
2021-03-31 $0.01B $0.05B 0.14
2020-12-31 $0.01B $0.05B 0.16
2020-09-30 $0.01B $0.06B 0.16
2020-06-30 $0.01B $0.07B 0.14
2020-03-31 $0.01B $0.07B 0.14
2019-12-31 $0.01B $0.05B 0.17
2019-09-30 $0.01B $0.06B 0.16
2019-06-30 $0.01B $0.06B 0.16
2019-03-31 $0.01B $0.06B 0.15
2018-12-31 $0.01B $0.06B 0.09
2018-09-30 $0.01B $0.08B 0.08
2018-06-30 $0.01B $0.08B 0.06
2018-03-31 $0.00B $0.09B 0.03
2017-12-31 $0.00B 0.00
2017-09-30 $0.07B $-0.05B -1.47
2017-06-30 $0.00B $0.00B 0.00
2016-12-31 $0.04B $-0.03B -1.35
2015-12-31 $0.02B $-0.01B -1.72
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.014B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00